Wednesday, February 10, 2010, 12:00PM AEST - The Australian Stockmarket closes in 4 hours and 5 minutes.
To create a watchlist or portfolio of shares, Register

Ardea Biosciences, Inc. (RDEA)

 8:00AM AEST: 14.56 USD  Up 0.04 (0.28%)  
 MORE ON RDEA 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 Ardea Biosciences, Inc. (NGM:RDEA) Delayed quote dataEdit
Last Trade:14.56 USD
Trade Time: 8:00AM AEST
Change:Up 0.04 (0.28%)
Prev Close:14.52
Open:14.59
Bid:14.00 x 1500
Ask:N/A
1y Target Est:22.83
Day's Range:14.50 - 14.93
52wk Range:8.78 - 21.35
Volume:209,292
Avg Vol (3m):104,554
Market Cap:268.12M
P/E (ttm):N/A
EPS (ttm):-2.14
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add RDEA to Portfolio   Download Data

 HEADLINES 
•Ardea Biosciences names Felix Baker to board
AP (Wed 5:08AM)
•ARDEA BIOSCIENCES, INC./DE Files SEC form 8-K, Change in Directors or Principal Officers
EDGAR Online (Wed 12:45AM)
•Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
PR Newswire (Wed 12:30AM)
•Ardea Biosciences to Present at the 12th Annual BIO CEO and Investor Conference
PR Newswire (Sat, Feb 6)
•Coverage initiated on Ardea Biosciences by Soleil
Briefing.com (Thu, Jan 28)
•ARDEA BIOSCIENCES, INC./DE Files SEC form 8-K, Regulation FD Disclosure
EDGAR Online (Tue, Jan 12)
•Ardea Biosciences rises on gout drug study results
AP (Fri, Jan 8)
•ARDEA BIOSCIENCES, INC./DE Files SEC form 8-K, Regulation FD Disclosure
EDGAR Online (Fri, Jan 8)
•Ardea Biosciences Reports Positive Results for RDEA594, its Lead Product Candidate for Gout, in Combination with Allopurinol or Febuxostat
PR Newswire (Fri, Jan 8)
•ARDEA BIOSCIENCES, INC./DE Files SEC form 8-K, Entry into a Material Definitive Agreement
EDGAR Online (Wed, Dec 23)
More Headlines for RDEA...
 ANALYST 
EPS Est (next year) (Dec-09) :-1.63
EPS Est (in 2 years) (Dec-10) :-1.75
Avg Rec (current)*:1.3
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Ardea Biosciences, Inc., a biotechnology company, focuses on the discovery and development of small-molecule therapeutics for the treatment of gout, human immunodeficiency virus (HIV), cancer, and inflammatory diseases in the United States.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
•Latest News•7 Indices